Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper

Nicola Silvestris, Antonella Argentiero, Laura Cosmai, Camillo Porta, Loreto Gesualdo, Giuliano Brunori, Oronzo Brunetti, Teresa Rampino, Simona Secondino, Gianpiero Rizzo, Paolo Pedrazzoli

Research output: Contribution to journalReview articlepeer-review

Abstract

The increasing availability of novel biological anticancer agents has greatly improved the outcome of several cancer patients; unfortunately, data regarding efficacy, safety and pharmacokinetics of many of these agents in patients with chronic renal disease or on hemodialysis are scanty. Furthermore these results are controversial and a treatment strategy has not yet been established. Therefore, the Associazione Italiana di Oncologia Medica and the Società italiana di Nefrologia undertook the present work aiming at providing health professionals with a tool for easier clinical management of target therapies in this setting of patients. A web-based search of MEDLINE/PubMed library data published from 2000 to June 2018 has been performed. More than one hundred papers, including recommendations and expert opinions, were selected and discussed by the authors. A panel of experts provided additional biological and clinical information, helping in clarifying some issues in the absence of clear-cut information from the literature.

Original languageEnglish
Pages (from-to)39-51
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume140
DOIs
Publication statusPublished - Aug 1 2019

Keywords

  • Cancer
  • Chronic kidney disease
  • End-stage renal disease
  • ESRD
  • Hemodialysis
  • Kidney failure
  • Renal impairment
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper'. Together they form a unique fingerprint.

Cite this